REPL - Replimune Group Inc Stock Price, Fair Value and News

10.36USD-0.12 (-1.15%)Market Closed

Market Summary

USD10.36-0.12

Market Closed

-1.15%

REPL Stock Price

View Fullscreen

REPL RSI Chart

REPL Valuation

Market Cap

636.3M

Price/Earnings (Trailing)

-2.95

Price/Sales (Trailing)

27.24

EV/EBITDA

-2.91

Price/Free Cashflow

-3.43

REPL Price/Sales (Trailing)

REPL Profitability

EBT Margin

-922.21%

Return on Equity

-57.62%

Return on Assets

-44.25%

Free Cashflow Yield

-29.15%

REPL Fundamentals

REPL Revenue

Revenue (TTM)

23.4M

Rev. Growth (Yr)

-7.51%

Rev. Growth (Qtr)

-4.42%

REPL Earnings

Earnings (TTM)

-215.8M

Earnings Growth (Yr)

-11.8%

Earnings Growth (Qtr)

-7.74%

Breaking Down REPL Revenue

Last 7 days

4.8%

Last 30 days

18.9%

Last 90 days

61.4%

Trailing 12 Months

-46.8%

How does REPL drawdown profile look like?

REPL Financial Health

Current Ratio

10.72

Debt/Equity

0.12

Debt/Cashflow

-4.14

REPL Investor Care

Shares Dilution (1Y)

6.30%

Diluted EPS (TTM)

-3.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	23.4M	0	0	0
2023	10.0M	15.8M	20.8M	23.8M
2022	1.7M	1.3M	1.7M	4.3M
2021	2.8M	2.9M	2.9M	2.4M
2020	3.1M	3.1M	3.3M	2.9M
2019	2.8M	3.3M	3.2M	2.6M
2018	2.3M	2.1M	2.1M	3.0M
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Replimune Group Inc

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

CEO	Mr. Philip Astley-Sparke F.S.A., FSA
WEBSITE	replimune.com
INDUSTRY	Biotechnology
EMPLOYEES	284

Replimune Group Inc Frequently Asked Questions

What is the ticker symbol for Replimune Group Inc? What does REPL stand for in stocks?

REPL is the stock ticker symbol of Replimune Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Replimune Group Inc (REPL)?

As of Fri Jul 26 2024, market cap of Replimune Group Inc is 636.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of REPL stock?

You can check REPL's fair value in chart for subscribers.

Is Replimune Group Inc a good stock to buy?

The fair value guage provides a quick view whether REPL is over valued or under valued. Whether Replimune Group Inc is cheap or expensive depends on the assumptions which impact Replimune Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for REPL.

What is Replimune Group Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, REPL's PE ratio (Price to Earnings) is -2.95 and Price to Sales (PS) ratio is 27.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. REPL PE ratio will change depending on the future growth rate expectations of investors.